Tyr536
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr536  -  IL2RB (human)

Site Information
LPLNTDAyLSLQELQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450934
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 ) , mutation of modification site ( 6 )
Disease tissue studied:
leukemia ( 1 , 2 ) , chronic lymphocytic leukemia ( 1 ) , T cell leukemia ( 2 ) , lymphoma ( 3 , 4 , 5 ) , Hodgkin's lymphoma ( 3 , 4 , 5 )
Relevant cell line - cell type - tissue:
BaF3 ('B lymphocyte, precursor') ( 6 ) , COS (fibroblast) ( 6 ) , F15R-Kit (T lymphocyte) ( 1 ) , HDLM-2 (lymphoid) ( 4 ) , Kit225 (T lymphocyte) ( 2 ) , L540 (lymphoid) ( 3 , 5 )

Upstream Regulation
Kinases, in vitro:
Lck (human) ( 8 )
Treatments:
IL-15 ( 1 ) , IL-2 ( 1 , 2 )

Downstream Regulation
Effects of modification on IL2RB:
molecular association, regulation ( 6 , 7 )
Effects of modification on biological processes:
apoptosis, inhibited ( 6 ) , cell growth, altered ( 6 )
Induce interaction with:
SHB (human) ( 6 ) , STAT5A (human) ( 7 ) , STAT5B (human) ( 7 )

References 

1

Arneja A, et al. (2014) Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 192, 123-35
24298013   Curated Info

2

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

3

Gu TL, et al. (2010) Identification of activated Tnk1 kinase in Hodgkin's lymphoma. Leukemia 24, 861-5
20090780   Curated Info

4

Gu T (2006) CST Curation Set: 1935; Year: 2006; Biosample/Treatment: cell line, HDLM-2/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Gu T (2006) CST Curation Set: 1936; Year: 2006; Biosample/Treatment: cell line, L540/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Lindholm CK (2002) IL-2 receptor signaling through the Shb adapter protein in T and NK cells. Biochem Biophys Res Commun 296, 929-36
12200137   Curated Info

7

Delespine-Carmagnat M, Bouvier G, Bertoglio J (2000) Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain. Eur J Immunol 30, 59-68
10602027   Curated Info

8

Delespine-Carmagnat M, et al. (1999) Biochemical analysis of interleukin-2 receptor beta chain phosphorylation by p56(lck). FEBS Lett 447, 241-6
10214954   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.